MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

MDT

89.73

+0.54%↑

VEEV

282.11

+0.97%↑

A

113.48

+0.27%↑

WBA

11.52

+0.09%↑

HQY

97.58

+1.43%↑

Search

MannKind Corp

Cerrado

SectorSalud

3.96 2.86

Resumen

Variación precio

24h

Actual

Mínimo

3.85

Máximo

3.99

Métricas clave

By Trading Economics

Ingresos

5.7M

13M

Ventas

1.6M

78M

P/B

Media del Sector

40.3

39.857

Margen de beneficio

16.793

Empleados

403

EBITDA

8.3M

27M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+140.26% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-282M

1.2B

Apertura anterior

1.1

Cierre anterior

3.96

Noticias sobre sentimiento de mercado

By Acuity

22%

78%

47 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

MannKind Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 jul 2025, 23:56 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- 2nd Update

16 jul 2025, 23:43 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Output Rises 1% as Takeover Campaign Continues

16 jul 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Ends Bid to Buy Seven & I Holdings -- Update

16 jul 2025, 22:38 UTC

Adquisiciones, fusiones, absorciones

Alimentation Couche-Tard Withdraws Seven & i Acquisition Proposal

16 jul 2025, 23:44 UTC

Charlas de Mercado

Gold Steady; Geopolitical Tensions in Middle East Support -- Market Talk

16 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Fall as Yen Strengthens -- Market Talk

16 jul 2025, 23:24 UTC

Charlas de Mercado

Australian Job Market Data to Shape RBA Calls -- Market Talk

16 jul 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Santos Now Expects 2025 Production of 90 Million-95 Million BOE

16 jul 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Santos Cuts Top End of 2025 Production Guidance

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Production Recovery Underway in Cooper Basin

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Over 200 Wells, Several Upstream Compressors in Cooper Basin Shut In

16 jul 2025, 23:17 UTC

Adquisiciones, fusiones, absorciones

Santos: Cooper Basin Production Impacted by Floods in 2Q

16 jul 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Santos: Pikka Phase 1 Project in Alasia 89% Complete

16 jul 2025, 23:16 UTC

Adquisiciones, fusiones, absorciones

Santos Keeps 2025 Major Development Project Capex Guidance Unchanged

16 jul 2025, 23:13 UTC

Adquisiciones, fusiones, absorciones

Santos Had Gearing of 20.5% at End-June, Excluding Operating Leases

16 jul 2025, 23:13 UTC

Adquisiciones, fusiones, absorciones

Santos Says Moomba CCS Phase 1 Project Performing to Expectations

16 jul 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Santos Narrows 2025 Unit Production Cost Guidance to US$7.00-US$7.40/BOE

16 jul 2025, 23:12 UTC

Adquisiciones, fusiones, absorciones

Santos 1H Free Cash Flow From Operations US$1.1 Billion

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Free Cash Flow From Operations US$620 Million

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Output 22.2 Million BOE

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Sales Volumes 23.9 Million BOE

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Sales Volumes Up 3% on 1Q

16 jul 2025, 23:11 UTC

Adquisiciones, fusiones, absorciones

Santos 2Q Oil, Natural Gas Output Up 1% on 1Q

16 jul 2025, 22:43 UTC

Charlas de Mercado

Alcoa Using High Costs of More Production to Battle Tariff -- Market Talk

16 jul 2025, 22:35 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

16 jul 2025, 22:35 UTC

Charlas de Mercado
Ganancias

Replacing Aluminum Imports With U.S. Production Not Seen Feasible -- Market Talk

16 jul 2025, 22:33 UTC

Charlas de Mercado
Ganancias

Alcoa Will Continue to Ship Aluminum Outside of the U.S. -- Market Talk

16 jul 2025, 22:28 UTC

Charlas de Mercado
Ganancias

Aluminum Price in U.S. Doesn't Offset Tariff Costs, Alcoa says -- Market Talk

16 jul 2025, 22:22 UTC

Charlas de Mercado
Ganancias

Market Talk Roundup: Latest on U.S. Politics

16 jul 2025, 22:22 UTC

Charlas de Mercado
Ganancias

Alcoa Considers Restart of Idle Capacity at Indiana Smelter -- Market Talk

Comparación entre iguales

Cambio de precio

MannKind Corp Esperado

Precio Objetivo

By TipRanks

140.26% repunte

Estimación a 12 meses

Media 9.25 USD  140.26%

Máximo 11 USD

Mínimo 7 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para MannKind Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.079 / 4.323Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

47 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.